Patent · US Active

Pegylated carfilzomib compounds

US10675353B2 · kind B2 · utility

1Cited by
1References
25Claims
0Family size

Assignee

Inventors

Key dates

Filing dateNov 5, 2019
Grant dateJun 9, 2020
Priority date
Expiry dateNov 5, 2039

Classification

  • Technology area (CPC C)Chemistry; Metallurgy
  • CPC primaryC08G2230/00
  • WIPO fieldPharmaceuticals
  • WIPO sectorChemistry

Abstract

The present invention provides a method of treating multiple myeloma using polymeric pegylated carfilzomib compounds, and pharmaceutically acceptable salts thereof, of Formula I wherein R1, R2, linker, PEG, n and o are as defined herein.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.